{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:27:05Z","timestamp":1792704425106,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00428-025-04081-x","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:57:51Z","timestamp":1743364671000},"page":"1199-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma"],"prefix":"10.1007","volume":"486","author":[{"given":"Yu-Hsuan","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaa Hoo","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsi","family":"Hsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-5028","authenticated-orcid":false,"given":"Yow-Ling","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"4081_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261\u2013280. https:\/\/doi.org\/10.1038\/nrgastro.2016.51","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4081_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4081_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E (2019) Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol 71:104\u2013114. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.013","journal-title":"J Hepatol"},{"key":"4081_CR4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ (2014) Cholangiocarcinoma. Lancet 383:2168\u20132179. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0","journal-title":"Lancet"},{"key":"4081_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","volume":"50","author":"MM Claessen","year":"2009","unstructured":"Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50:158\u2013164. https:\/\/doi.org\/10.1016\/j.jhep.2008.08.013","journal-title":"J Hepatol"},{"key":"4081_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1046\/j.1365-2168.2002.02143.x","volume":"89","author":"P Watanapa","year":"2002","unstructured":"Watanapa P, Watanapa WB (2002) Liver fluke-associated cholangiocarcinoma. Br J Surg 89:962\u2013970. https:\/\/doi.org\/10.1046\/j.1365-2168.2002.02143.x","journal-title":"Br J Surg"},{"key":"4081_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","volume":"57","author":"WC Palmer","year":"2012","unstructured":"Palmer WC, Patel T (2012) Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 57:69\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.022","journal-title":"J Hepatol"},{"key":"4081_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","volume":"15","author":"SI Ilyas","year":"2018","unstructured":"Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95\u2013111. https:\/\/doi.org\/10.1038\/nrclinonc.2017.157","journal-title":"Nat Rev Clin Oncol"},{"key":"4081_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jamcollsurg.2015.09.005","volume":"221","author":"B Groot Koerkamp","year":"2015","unstructured":"Groot Koerkamp B, Wiggers JK, Allen PJ, Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D\u2019Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, Jarnagin WR, van Gulik TM (2015) Recurrence rate and pattern of perihilar cholangiocarcinoma after curative intent resection. J Am Coll Surg 221:1041\u20131049. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2015.09.005","journal-title":"J Am Coll Surg"},{"key":"4081_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2188\/jea.je20180007","volume":"29","author":"S Kamsa-Ard","year":"2019","unstructured":"Kamsa-Ard S, Luvira V, Suwanrungruang K, Kamsa-Ard S, Luvira V, Santong C, Srisuk T, Pugkhem A, Bhudhisawasdi V, Pairojkul C (2019) Cholangiocarcinoma trends, incidence, and relative survival in Khon Kaen, Thailand from 1989 through 2013: a population-based cancer registry study. J Epidemiol 29:197\u2013204. https:\/\/doi.org\/10.2188\/jea.je20180007","journal-title":"J Epidemiol"},{"key":"4081_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.surg.2017.08.011","volume":"163","author":"K Komaya","year":"2018","unstructured":"Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J, Nagino M (2018) Recurrence after curative-intent resection of perihilar cholangiocarcinoma: analysis of a large cohort with a close postoperative follow-up approach. Surgery 163:732\u2013738. https:\/\/doi.org\/10.1016\/j.surg.2017.08.011","journal-title":"Surgery"},{"key":"4081_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/736049","volume":"2015","author":"P Lindner","year":"2015","unstructured":"Lindner P, Rizell M, Hafstrom L (2015) The impact of changed strategies for patients with cholangiocarcinoma in this millenium. HPB Surg 2015:736049. https:\/\/doi.org\/10.1155\/2015\/736049","journal-title":"HPB Surg"},{"key":"4081_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/0284186x.2019.1590634","volume":"58","author":"M Strijker","year":"2019","unstructured":"Strijker M, Belkouz A, Van Der Geest LG, Van Gulik TM, Van Hooft JE, De Meijer VE, Haj Mohammad N, De Reuver PR, Verheij J, De Vos-Geelen J, Wilmink JW, Groot Koerkamp B, Kl\u00fcmpen H-J, Besselink MG (2019) Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. Acta Oncol 58:1048\u20131055. https:\/\/doi.org\/10.1080\/0284186x.2019.1590634","journal-title":"Acta Oncol"},{"key":"4081_CR14","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, Tureci O (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547","journal-title":"Clin Cancer Res"},{"key":"4081_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh P, Toom S, Huang Y (2017) Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 10:105. https:\/\/doi.org\/10.1186\/s13045-017-0473-4","journal-title":"J Hematol Oncol"},{"key":"4081_CR16","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA (2023) ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 29:3882\u20133891. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0204","journal-title":"Clin Cancer Res"},{"key":"4081_CR17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401:1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"4081_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bbamem.2007.10.018","volume":"1778","author":"G Krause","year":"2008","unstructured":"Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE (2008) Structure and function of claudins. Biochim Biophys Acta 1778:631\u2013645. https:\/\/doi.org\/10.1016\/j.bbamem.2007.10.018","journal-title":"Biochim Biophys Acta"},{"key":"4081_CR19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bbamem.2007.08.018","volume":"1778","author":"L Gonzalez-Mariscal","year":"2008","unstructured":"Gonzalez-Mariscal L, Tapia R, Chamorro D (2008) Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 1778:729\u2013756. https:\/\/doi.org\/10.1016\/j.bbamem.2007.08.018","journal-title":"Biochim Biophys Acta"},{"key":"4081_CR20","doi-asserted-by":"publisher","first-page":"9603","DOI":"10.1158\/0008-5472.CAN-05-2782","volume":"65","author":"PJ Morin","year":"2005","unstructured":"Morin PJ (2005) Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65:9603\u20139606. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2782","journal-title":"Cancer Res"},{"key":"4081_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1749-6632.2000.tb05246.x","volume":"915","author":"JM Mullin","year":"2000","unstructured":"Mullin JM, Laughlin KV, Ginanni N, Marano CW, Clarke HM, Peralta Soler A (2000) Increased tight junction permeability can result from protein kinase C activation\/translocation and act as a tumor promotional event in epithelial cancers. Ann N Y Acad Sci 915:231\u2013236. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05246.x","journal-title":"Ann N Y Acad Sci"},{"key":"4081_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1007\/s10620-012-2043-5","volume":"57","author":"T Okugawa","year":"2012","unstructured":"Okugawa T, Oshima T, Chen X, Hori K, Tomita T, Fukui H, Watari J, Matsumoto T, Miwa H (2012) Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers. Dig Dis Sci 57:1562\u20131567. https:\/\/doi.org\/10.1007\/s10620-012-2043-5","journal-title":"Dig Dis Sci"},{"key":"4081_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/jjco\/hyz068","volume":"49","author":"C Rohde","year":"2019","unstructured":"Rohde C, Yamaguchi R, Mukhina S, Sahin U, Itoh K, Tureci O (2019) Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Jpn J Clin Oncol 49:870\u2013876. https:\/\/doi.org\/10.1093\/jjco\/hyz068","journal-title":"Jpn J Clin Oncol"},{"key":"4081_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O Tureci","year":"2019","unstructured":"Tureci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M (2019) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol 30:1487\u20131495. https:\/\/doi.org\/10.1093\/annonc\/mdz199","journal-title":"Ann Oncol"},{"key":"4081_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-6-186","volume":"6","author":"KJ Hewitt","year":"2006","unstructured":"Hewitt KJ, Agarwal R, Morin PJ (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6:186. https:\/\/doi.org\/10.1186\/1471-2407-6-186","journal-title":"BMC Cancer"},{"key":"4081_CR26","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/ijc.28857","volume":"135","author":"P Micke","year":"2014","unstructured":"Micke P, Mattsson JS, Edlund K, Lohr M, Jirstrom K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Ponten F, Ekman S, Hengstler J, Woll S, Sahin U, Tureci O (2014) Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 135:2206\u20132214. https:\/\/doi.org\/10.1002\/ijc.28857","journal-title":"Int J Cancer"},{"key":"4081_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14670\/HH-25.83","volume":"25","author":"A Ouban","year":"2010","unstructured":"Ouban A, Ahmed AA (2010) Claudins in human cancer: a review. Histol Histopathol 25:83\u201390. https:\/\/doi.org\/10.14670\/HH-25.83","journal-title":"Histol Histopathol"},{"key":"4081_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000101049","volume":"74","author":"J Ueda","year":"2007","unstructured":"Ueda J, Semba S, Chiba H, Sawada N, Seo Y, Kasuga M, Yokozaki H (2007) Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 74:32\u201341. https:\/\/doi.org\/10.1159\/000101049","journal-title":"Pathobiology"},{"key":"4081_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S Woll","year":"2014","unstructured":"Woll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Tureci O (2014) Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer 134:731\u2013739. https:\/\/doi.org\/10.1002\/ijc.28400","journal-title":"Int J Cancer"},{"key":"4081_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijsu.2013.11.022","volume":"12","author":"KH Jun","year":"2014","unstructured":"Jun KH, Kim JH, Jung JH, Choi HJ, Chin HM (2014) Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int J Surg 12:156\u2013162. https:\/\/doi.org\/10.1016\/j.ijsu.2013.11.022","journal-title":"Int J Surg"},{"key":"4081_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/path.1922","volume":"208","author":"Y Sanada","year":"2006","unstructured":"Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W (2006) Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol 208:633\u2013642. https:\/\/doi.org\/10.1002\/path.1922","journal-title":"J Pathol"},{"key":"4081_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jclinpath-2011-200400","volume":"65","author":"Y Soini","year":"2012","unstructured":"Soini Y, Takasawa A, Eskelinen M, Juvonen P, Karja V, Hasegawa T, Murata M, Tanaka S, Kojima T, Sawada N (2012) Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation. J Clin Pathol 65:431\u2013436. https:\/\/doi.org\/10.1136\/jclinpath-2011-200400","journal-title":"J Clin Pathol"},{"key":"4081_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1369\/0022155411420569","volume":"59","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M (2011) Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 59:942\u2013952. https:\/\/doi.org\/10.1369\/0022155411420569","journal-title":"J Histochem Cytochem"},{"key":"4081_CR34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX (2022) Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 14:1252\u20131264. https:\/\/doi.org\/10.4251\/wjgo.v14.i7.1252","journal-title":"World J Gastrointest Oncol"},{"key":"4081_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00428-021-03207-1","volume":"480","author":"S Asaka","year":"2022","unstructured":"Asaka S, Nakajima T, Ida K, Asaka R, Kobayashi C, Ito M, Miyamoto T, Uehara T, Ota H (2022) Clinicopathological and prognostic significance of immunophenotypic characterization of endocervical adenocarcinoma using CLDN18, CDH17, and PAX8 in association with HPV status. Virchows Arch 480:269\u2013280. https:\/\/doi.org\/10.1007\/s00428-021-03207-1","journal-title":"Virchows Arch"},{"key":"4081_CR36","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1053\/j.gastro.2018.08.041","volume":"155","author":"SJ Hagen","year":"2018","unstructured":"Hagen SJ, Ang LH, Zheng Y, Karahan SN, Wu J, Wang YE, Caron TJ, Gad AP, Muthupalani S, Fox JG (2018) Loss of tight junction protein claudin 18 promotes progressive neoplasia development in mouse stomach. Gastroenterology 155:1852\u20131867. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.041","journal-title":"Gastroenterology"},{"key":"4081_CR37","doi-asserted-by":"publisher","first-page":"G1106","DOI":"10.1152\/ajpgi.00158.2007","volume":"293","author":"B Jovov","year":"2007","unstructured":"Jovov B, Van Itallie CM, Shaheen NJ, Carson JL, Gambling TM, Anderson JM, Orlando RC (2007) Claudin-18: a dominant tight junction protein in Barrett\u2019s esophagus and likely contributor to its acid resistance. Am J Physiol Gastrointest Liver Physiol 293:G1106-1113. https:\/\/doi.org\/10.1152\/ajpgi.00158.2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4081_CR38","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1002\/ijc.31734","volume":"143","author":"J Luo","year":"2018","unstructured":"Luo J, Chimge NO, Zhou B, Flodby P, Castaldi A, Firth AL, Liu Y, Wang H, Yang C, Marconett CN, Crandall ED, Offringa IA, Frenkel B, Borok Z (2018) CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro. Int J Cancer 143:3169\u20133180. https:\/\/doi.org\/10.1002\/ijc.31734","journal-title":"Int J Cancer"},{"key":"4081_CR39","doi-asserted-by":"publisher","first-page":"e74757","DOI":"10.1371\/journal.pone.0074757","volume":"8","author":"T Oshima","year":"2013","unstructured":"Oshima T, Shan J, Okugawa T, Chen X, Hori K, Tomita T, Fukui H, Watari J, Miwa H (2013) Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS One 8:e74757. https:\/\/doi.org\/10.1371\/journal.pone.0074757","journal-title":"PLoS One"},{"key":"4081_CR40","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.bbamcr.2016.02.015","volume":"1863","author":"S Shimobaba","year":"2016","unstructured":"Shimobaba S, Taga S, Akizuki R, Hichino A, Endo S, Matsunaga T, Watanabe R, Yamaguchi M, Yamazaki Y, Sugatani J, Ikari A (2016) Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells. Biochim Biophys Acta 1863:1170\u20131178. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.02.015","journal-title":"Biochim Biophys Acta"},{"issue":"924\u2013939","key":"4081_CR41","doi-asserted-by":"publisher","first-page":"e911","DOI":"10.1053\/j.gastro.2021.05.057","volume":"161","author":"H Singh","year":"2021","unstructured":"Singh H, Ha K, Hornick JL, Madha S, Cejas P, Jajoo K, Singh P, Polak P, Lee H, Shivdasani RA (2021) Hybrid stomach-intestinal chromatin states underlie human Barrett\u2019s metaplasia. Gastroenterology 161(924\u2013939):e911. https:\/\/doi.org\/10.1053\/j.gastro.2021.05.057","journal-title":"Gastroenterology"},{"key":"4081_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2017.05.033","volume":"403","author":"K Takasawa","year":"2017","unstructured":"Takasawa K, Takasawa A, Osanai M, Aoyama T, Ono Y, Kono T, Hirohashi Y, Murata M, Sawada N (2017) Claudin-18 coupled with EGFR\/ERK signaling contributes to the malignant potentials of bile duct cancer. Cancer Lett 403:66\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.033","journal-title":"Cancer Lett"},{"key":"4081_CR43","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1172\/JCI90429","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou B, Flodby P, Luo J, Castillo DR, Liu Y, Yu FX, McConnell A, Varghese B, Li G, Chimge NO, Sunohara M, Koss MN, Elatre W, Conti P, Liebler JM, Yang C, Marconett CN, Laird-Offringa IA, Minoo P, Guan K, Stripp BR, Crandall ED, Borok Z (2018) Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Invest 128:970\u2013984. https:\/\/doi.org\/10.1172\/JCI90429","journal-title":"J Clin Invest"},{"key":"4081_CR44","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/PAS.0000000000001583","volume":"44","author":"WT Li","year":"2020","unstructured":"Li WT, Jeng YM, Yang CY (2020) Claudin-18 as a marker for identifying the stomach and pancreatobiliary tract as the primary sites of metastatic adenocarcinoma. Am J Surg Pathol 44:1643\u20131648. https:\/\/doi.org\/10.1097\/PAS.0000000000001583","journal-title":"Am J Surg Pathol"},{"key":"4081_CR45","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, An JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK, Kim ST (2020) Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res 9:3367\u20133374. https:\/\/doi.org\/10.21037\/tcr-19-1876","journal-title":"Transl Cancer Res"},{"key":"4081_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00428-011-1092-z","volume":"459","author":"A Shinozaki","year":"2011","unstructured":"Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M (2011) Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Arch 459:73\u201380. https:\/\/doi.org\/10.1007\/s00428-011-1092-z","journal-title":"Virchows Arch"},{"key":"4081_CR47","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH (2023) Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 29:2133\u20132141. https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat Med"},{"key":"4081_CR48","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, Tureci O, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, Dhaene K, Wiechen K, Huber C, Maurus D, Arozullah A, Park JW, Schuler M, Al-Batran SE (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32:609\u2013619. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005","journal-title":"Ann Oncol"},{"key":"4081_CR49","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter PL, Riddell SR (2017) Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res 23:3061\u20133071. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2083","journal-title":"Clin Cancer Res"},{"key":"4081_CR50","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, Zhang X, Lu Z, Lu M, Yuan J, Wang Z, Wang Y, Peng X, Gao H, Liu Z, Wang H, Yuan D, Xiao J, Ma H, Wang W, Li Z, Shen L (2022) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28:1189\u20131198. https:\/\/doi.org\/10.1038\/s41591-022-01800-8","journal-title":"Nat Med"},{"key":"4081_CR51","doi-asserted-by":"publisher","first-page":"6977","DOI":"10.2147\/CMAR.S330637","volume":"13","author":"J Liang","year":"2021","unstructured":"Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X (2021) A CLDN18.2-targeting bispecific T cell co-stimulatory activator for cancer immunotherapy. Cancer Manag Res 13:6977\u20136987. https:\/\/doi.org\/10.2147\/CMAR.S330637","journal-title":"Cancer Manag Res"},{"key":"4081_CR52","doi-asserted-by":"publisher","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","volume":"9","author":"G Zhu","year":"2019","unstructured":"Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, Rickert M, Holz C, Aschenbrenner L, Yang AH, Kraynov E, Evering W, Obert L, Lee C, Sai T, Mistry T, Lindquist KC, Van Blarcom T, Strop P, Chaparro-Riggers J, Liu SH (2019) Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer. Sci Rep 9:8420. https:\/\/doi.org\/10.1038\/s41598-019-44874-0","journal-title":"Sci Rep"},{"key":"4081_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K (2024) Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol 21:354\u2013369. https:\/\/doi.org\/10.1038\/s41571-024-00874-2","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04081-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04081-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04081-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T05:57:48Z","timestamp":1751349468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04081-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["4081"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04081-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Chi-Mei Medical Center with approval number 09912003.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}